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Abstract
The Reperfusion Injury Salvage Kinase (RISK) pathway is considered the main pro-survival kinase cascade mediating the ischaemic precondi-
tioning (IPC) cardioprotective effect. To assess the role of PI3K-Akt, its negative regulator PTEN and other pro-survival proteins such as ERK
and STAT3 in the context of IPC, C57BL/6 mouse hearts were retrogradely perfused in a Langendorff system and subjected to 4 cycles of
5 min. ischaemia and 5 min. reperfusion prior to 35 min. of global ischaemia and 120 min. of reperfusion. Wortmannin, a PI3K inhibitor, was
administered either at the stabilization period or during reperfusion. Infarct size was assessed using triphenyl tetrazolium staining, and phos-
phorylation levels of Akt, PTEN, ERK, GSK3b and STAT3 were evaluated using Western blot analyses. IPC reduced infarct size in hearts sub-
jected to lethal ischaemia and reperfusion, but this effect was lost in the presence of Wortmannin, whether it was present only during
preconditioning or only during early reperfusion. IPC increased the levels of Akt phosphorylation during both phases and this effect was fully
abrogated by PI3K, whilst its downstream GSK3b was phosphorylated only during the trigger phase after IPC. Both PTEN and STAT3 were
phosphorylated during both phases after IPC, but this was PI3K independent. IPC increases ERK phosphorylation during both phases, being
only PI3K-dependent during the IPC phase. In conclusion, PI3K-Akt plays a major role in IPC-induced cardioprotection. However, PTEN, ERK
and STAT3 are also phosphorylated by IPC through a PI3K-independent pathway, suggesting that cardioprotection is mediated through more
than one cell signalling cascade.
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Introduction
Acute myocardial infarction (AMI) remains a leading cause of mortal-
ity worldwide [1]. Timely reperfusion is the most effective treatment
to limit myocardial infarct size (IS) and, consequently, to improve
clinical outcome. Substantial effort has been made to implement early
reperfusion therapy, which is crucial to salvage myocardial tissue,
although paradoxically, injury still occurs as a consequence of reper-
fusion itself and remains an important target. Therefore, the develop-
ment of novel therapeutic strategies to further reduce myocardial IS
and preserve cardiac function [2] is still required.
IPC whereby brief cycles of coronary occlusion and reperfusion
elicits protection was reported over 3 decades ago [3, 4] and has
been replicated in all species examined [5], including humans [6],
and has shown protection when applied to other organs and tissues
[7]. Importantly, other than reperfusion itself, IPC is considered the
most powerful intervention available to protect the heart against
myocardial ischaemia reperfusion injury (IRI) and has become the
paradigm for cardioprotection [8].
IPC results in the recruitment of signalling pathways comprising
protein kinases and phosphatases that converge on the mitochondria
[7]. The RISK pathway is considered the main pro-survival kinase
cascade mediating the IPC-induced protective effect and encom-
passes two parallel signalling cascades: PI3K-Akt and MEK1-ERK1/2
[8]. Its activation not only mediates the protection induced by IPC,
but also by other conditioning forms (pre-, post-, remote and phar-
macological conditioning), and therefore appears to be a universal
signalling paradigm for cardioprotection. Other alternative pathways,
such as the Survivor Activator Factor Enhancement (SAFE) pathway
comprising TNFa/STAT3, have also been proposed as IPC-induced
protection mediators [9].
A biphasic RISK activation response has been observed: occurring
first during the preconditioning cycles (or ‘trigger’ phase) and then
again during the first few minutes of reperfusion (‘mediator’ phase)
[8, 10]. Although the significance of the RISK pathways is generally
accepted, the relative importance of the activation of these kinases
*Correspondence to: Derek M YELLON
E-mail: d.yellon@ucl.ac.uk
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
doi: 10.1111/jcmm.13394
J. Cell. Mol. Med. Vol XX, No X, 2017 pp. 1-10
and phosphatases, either at the trigger phase or exclusively at the
mediator phase, remains to be fully elucidated. The activation of both
RISK and SAFE pathways has been demonstrated to occur at these
two time-points in IPC studies [4], but there is a lack of comprehen-
sive studies assessing the integrative or coordinated role of these sig-
nalling cascades. Cardioprotective signalling cascades have been
mostly simplified in the literature to make its logical order more
understandable. Crosstalk between the two components of the RISK
pathway [11, 12] and between the RISK and the SAFE pathways [13,
14] have been described in only a few studies.
The aim of this study was to systematically characterize the role
of PI3K-Akt component of the RISK pathway, as well as its counter
regulatory protein, PTEN in mediating the IPC cardioprotective effect
during both the trigger phase and the reperfusion stage. In principle,
both the activation (phosphorylation) of PI3K and the inactivation
(also through phosphorylation) of PTEN should be expected to acti-
vate Akt and thus induce cardioprotection. We also aimed to further
investigate the interplay between the PI3K-Akt pathway and their par-
allel ERK and STAT3 cascades at both time-points.
Materials and methods
Animals and chemicals
All procedures were performed in The Hatter Cardiovascular Institute,
University College London, in strict accordance with the Home Office
(United Kingdom) Guidance on Research and Testing using animals and
the Animals (Scientific Procedures) Act of 1986.
Animals used were male C57BL/6 mice (9–12 weeks, 24–28 g
weight), all of them obtained pathogen free from one supplier and
housed under identical conditions.
Wortmannin, CAS 19545-26-7, the PI3 kinase inhibitor, was pur-
chased from Merck Millipore (Nottingham, UK), and its concentration
dose was chosen based on previous publications [13, 15]. Dimethyl sul-
foxide from BDH (Poole, UK) was used as the solvent for Wortmannin
at a final concentration in the perfusion buffer of not more than 0.01%,
as well as a vehicle control for the rest of the groups.
Experimental design and study protocol
A total of 58 animals were used, although three hearts were excluded
before randomization as they failed predefined exclusion criteria (see
below). Therefore, 55 animals were randomly allocated to treatment
groups in two separate experiments:
(1) Study of infarct size. The effect on myocardial IS following
IPC 4 cycles was studied using wortmannin 100 nM adminis-
tered during the IPC protocol, or at reperfusion. The IPC proto-
col consisted of four cycles of 5 min. ischaemia and 5 min.
reperfusion and was chosen based on previous publications
demonstrating a reduction in myocardial IS [16, 17] (Fig. 1A).
(2) Study of phosphorylated protein levels. Activated levels
of kinases and phosphatases involved in IPC-induced cardio-
protection were systematically studied in two sections, as
summarized in Figure 1B. In the first, phosphorylated pro-
teins were measured at the trigger phase in three treatment
groups as follows: (i) control; (ii) IPC; and (iii) wortmannin
plus IPC. In the second section, phosphorylated kinases were
measured after 5 min. reperfusion in four treatment groups
as follows: (i) control; (ii) IPC; (iii) IPC plus wortmannin dur-
ing trigger phase; and (iv) IPC plus wortmannin during medi-
ator phase.
In comparison with the protocols aimed at assessing myocardial
IS, for those experiments aimed to evaluate protein phosphorylation
levels, the period of ischaemia was reduced to 15 min. and reperfu-
sion shortened to 5 min. Shorter protocols of IRI are well accepted in
literature [17, 18] on the basis of (i) obtaining enough non-necrotic
tissue to evaluate kinase activation and (ii) evaluate the key moment
where the protection is elicited by kinase activation and mPTP opening
delay [19, 20].
The sample size for the evaluation of myocardial IS was estimated
based on previous publications [16], whilst for Western blot analysis,
the sample size was chosen in line with convention [21]. Reproducible
randomization sequences were used to allocate mice using STATA version
13.1. (StataCorp, College Station, TX, USA).
Langendorff isolated perfused mouse heart
Terminal anaesthesia and anticoagulation with an intraperitoneal injec-
tion of 60 mg/kg sodium pentobarbitone and 100 IU heparin were
administered to mice, respectively. Hearts were then excised and imme-
diately submerged in ice-cold modified Krebs–Henseleit buffer (com-
posed of 118 mmol/l NaCl, 25 mmol/l NaHCO3, 11 mmol/l glucose,
4.7 mmol/l KCl, 1.22 mmol/l MgSO4.7H20, 1.21 mmol/l KH2PO4 and
1.84 mmol/l CaCl2.2H20). Hearts were then cannulated with a 21-gauge
cannula and retrogradely perfused, on a murine Langendorff system, at
80 mm Hg pressure. Both heart isolation and Langendorff perfusion
were carried out with filtered modified Krebs–Henseleit buffer aerated
with a mixture of O2 (95%) and CO2 (5%) to maintain pH at
7.40  0.3, as described previously [16].
Predefined exclusion criteria were as follows: (i) more than 4 min.
time between heart excision and the beginning of perfusion in the Lan-
gendorff mode; (ii) temperature above or below the 37  0.5°C range;
and (iii) buffer flow rate of the isolated heart of <1 ml/min. or more
than 6.5 ml/min. on the Langendorff preparation during the stabilization
period. After assessing for exclusion criteria in an initial 20 min. stabi-
lization period, hearts were subjected to the experimental protocols.
Myocardial infarct size
Myocardial IS was assessed after global ischaemia and reperfusion by
injecting 5 ml of 2,3,5-triphenyl tetrazolium chloride in phosphate-buf-
fered saline through the aorta and incubating the heart for 10 min. at
37°C to delineate the infarcted (white) versus viable (red) tissue [22].
Hearts were frozen overnight at – 20°C and sectioned perpendicularly to
the long axis the day after. The heart slices were subsequently trans-
ferred into 10% formalin buffer for 1 hr. Images were taken and coded
to blind the analyser. Planimetry analysis using Image J version 1.47
(NIH, Bethesda, Maryland, USA) was performed to accurately quantify
the percentage of myocardial IS.
2 ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Western blot analyses
Hearts prepared for Western blot analysis were collected following the
protocols illustrated in Figure 1B and thereafter snap-frozen in liquid
nitrogen. The tissue was then stored at 80°C until further processing.
The tissue was homogenized in protein lysis buffer, containing Tris pH
6.8 [100 nM], NaCl [300 Mm], NP40 0.5%, Halt protease inhibitor cock-
tail, Halt phosphatase inhibitor cocktail, 0.5 M EDTA (all from Thermo
Scientific, Loughborough, UK) and adjusted to pH 7.4. Homogenates
were then sonicated before being centrifuged for 10 min. at 10,000 g at
4°C to remove debris and DNA. Protein content were then determined
using bicinchoninic acid (BCA) protein assay reagent (Sigma-Aldrich, Gil-
lingham, UK) and protein levels corrected accordingly to ensure equal
protein loading. NuPAGE LDS Sample Buffer (4X) (Thermo Fisher
Scientific) plus 5%b-mercaptothanol were added, and the samples were
denatured by heating to 100°C for 10 min. Samples were loaded on
NuPAGE Novex 10% Bis-Tris protein gels (Thermo Fisher Scientific,
Loughborough, UK) using the Mini Protean III system (Bio-Rad, Watford,
UK). Proteins were electro-transferred onto nitrocellulose blotting mem-
brane (GE Healthcare Life Science, Amershamm UK) using wet transfer
in a Bio-Rad Mini Trans-Blot. The membranes were blocked by incubat-
ing in 5% bovine serum albumin/PBS tween and subsequently incubated
with appropriate primary antibodies at 4°C overnight.
Primary antibodies used were acquired from Cell Signaling Technol-
ogy (Leiden, The Netherlands): Akt (#9272), Phospho-Akt (Ser473)
(#9271), Phospho-Akt (Thr308) (#2965), ERK1/2 (#9102), Phospho-
ERK1/2 (Thr202/Tyr204) (#9101), GSK-3b (#9315), Phospho-GSK-3b
(Ser9) (#5558), Stat3 (#9139), Phospho-Stat3 (Tyr705) (#9145), Phos-
pho-PTEN (Ser380) (#9551) and PTEN (#9552). Anti-GAPDH (mAbcam,
#9484) was used as loading control. The day after, membranes were
probed with secondary infrared fluorescence antibodies. Levels of pro-
tein were quantified using the Odyssey imaging system from Li-Cor Bio-
sciences (Image Studio Lite Ver 5.2, Cambridge, UK).
Statistical analyses
Normal distribution of each data subset was tested using graphical
methods and the Kolmogorov–Smirnov method. All values are pre-
sented as mean  standard error of the mean. If normally distributed,
continuous data were compared using one-way analysis of variance
followed by post hoc pairwise comparisons to the control group using
the Dunnett’s test. If highly skewed distributed, the nonparametric
Kruskal–Wallis test was used with subsequent post hoc pairwise com-
parisons to the control group adjusted by the Dunn’s test. A P value of
<0.05 was considered statistically significant. STATA software, version
13.1 (StataCorp) and GraphPad Prism version 6.00 (GraphPad Software,
La Jolla, CA, USA) were used to perform both the analysis and the
graphics. The results were reported according to the ARRIVE guidelines
for reporting animal research [7].
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Fig. 1 Study design and experimental protocols. Panel (A). Study design for IS determination protocols in the context of IPC and wortmannin (W) before
and after index ischaemia. Four different experimental protocols were tested as follows: (i) control; (ii) IPC 4 cycles of 5 min. ischaemia and 5 min.
reperfusion per cycle; (iii) IPC 4 cycles in the context of wortmannin administered during the stabilization period and IPC protocol; and (iv) IPC 4 cycles
plus the administration of wortmannin upon reperfusion. Black boxes represent periods of ischaemia, white boxes represent periods of perfusion with
Krebs–Henseleit buffer at 80 mm Hg, and green boxes represent the perfusion of wortmannin 100 nM. Panel (B). Study design to compare Akt and ERK
phosphorylation analysis using Western blot. Four different experimental protocols were tested as follows: (i) control; (ii) IPC 4 cycles of 5 min. ischae-
mia and 5 min. reperfusion per cycle; (iii) IPC 4 cycles in the context of wortmannin administered during the stabilization period and IPC protocol; and
(iv) IPC 4 cycles plus the administration of wortmannin upon reperfusion. Black boxes represent periods of ischaemia, white boxes represent periods of
perfusion with Krebs–Henseleit buffer at 80 mm Hg, and green boxes represent the perfusion of wortmannin 100 nM. Arrows represent the moment
where samples were collected (in red all samples collected after IPC protocol, known as trigger phase; in green all samples collected at reperfusion).
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Results
PI3K mediates the IPC protective effect against
myocardial IRI
To investigate the role of the PI3K-AKT cascade in IPC-induced car-
dioprotection, isolated perfused mouse hearts were subjected to
35 min. global ischaemia, followed by 2-hr reperfusion. IPC resulted
in reduction in IS compared with the control group (21  4 versus
59  5%, P < 0.001) (Fig. 2). Administration of wortmannin either
during the trigger phase of the IPC protocol or during the mediator
phase abrogated its IS-limiting effect when compared to control
group (46  5%, P = 0.158; and 46  4, P = 0.154, respectively)
(Fig. 2).
PI3K mediates IPC-induced activation of Akt
To confirm the activation of Akt during the IPC trigger phase and the
early phase of reperfusion both of the main Akt phosphorylation sites
(Ser-473 and Thr-308) were studied. As expected, IPC increased Akt
phosphorylation in the trigger phase at both sites (Ser-473:
2.6  0.5-fold, P = 0.010 versus control; and Thr-308: 2.6  0.5-
fold versus control, P = 0.034), and phosphorylation was prevented
when wortmannin was applied during the IPC trigger phase (Fig. 3A
and C). Likewise, IPC increased the phosphorylation of Akt during the
mediator phase of reperfusion (Ser-473: 2.4  0.6-fold versus con-
trol, P < 0.001; and Thr-308: 3.1  0.7-fold versus control,
P = 0.001). However, this phosphorylation was consistently
abrogated when wortmannin was administered either during the
trigger or mediator phase (Fig. 3B and D).
IPC phosphorylates GSK3b at the trigger phase,
but not the mediator phase
To explore the downstream targets activated by PI3K-Akt both at the
trigger phase and upon reperfusion, we investigated the role of the
serine/threonine kinase GSK3b. In contrast to many protein kinases,
GSK3b is active in resting cells and inactivated by phosphorylation
[23]. On stimulation, GSK3b is phosphorylated at serine 9, resulting
in inhibition of its kinase activity. As illustrated in Figure 3E, IPC
caused an increase in GSK3b phosphorylation during the trigger
phase (3.2  0.9-fold versus control, P = 0.007), which was blocked
by wortmannin. On the contrary, GSK3b was not significantly phos-
phorylated at reperfusion in preconditioned hearts compared to con-
trol group (1.4  0.2-fold versus control, P = 0.742). Moreover, the
administration of wortmannin either during the trigger phase or medi-
ator phase did not affect GSK3b phosphorylation levels when mea-
sured at reperfusion (Fig. 3F).
IPC phosphorylates PTEN through a PI3K-
independent mechanism
PTEN is a phosphatase that counter regulates the PI3K/AKT signalling
pathway [24]. While phosphorylation by PI3K stimulates Akt activity,
PTEN dephosphorylates and down-regulates Akt activity. The phos-
phorylated form of PTEN is considered inactivated and is therefore a
major negative regulator of the RISK pathway [25]. PTEN phosphory-
lation was significantly increased immediately following an IPC stimu-
lus (2.2  0.6-fold versus control, P = 0.022). Interestingly, this
was not affected by the administration of wortmannin (Fig. 3F). IPC
was also associated with an increase in phosphorylated PTEN during
the mediator phase (2.0  0.3-fold versus control, P = 0.042), and
again, this was not affected by the presence of wortmannin during
either the trigger or mediator phases (Fig. 3H).
IPC-induced ERK activation involves PI3K during
the trigger phase, but not at reperfusion
During the IPC trigger phase, phosphorylated levels of ERK were sig-
nificantly increased by IPC (3.0  0.6-fold times compared to con-
trol, P = 0.016). This was partially abrogated by wortmannin, such
that there was no longer a significant increase in ERK phosphorylation
during the trigger phase after IPC (Fig. 4A). IPC also caused a signifi-
cant increase in ERK phosphorylation during the mediator phase
(2.6  0.6-fold increase for IPC, P = 0.016), but in contrast to the
response observed in the trigger phase, this was unaffected by the
administration of wortmannin (IPC + wortmannin during trigger
phase: 2.7  0.2-fold, P = 0.009; IPC + wortmannin during the
















No intervention Wortmannin 100 nM
IPC IPC+W
Fig. 2 Role of PI3K in the protective effect of IPC at the trigger phase
and at reperfusion. Scatter dot blots: black lines represent
mean  S.E.M., and circles represent individual animal data. Myocardial
infarct size was significantly smaller with IPC compared to control
group and either the administration of Wortmannin before or after
ischaemia index abolished the cardioprotective effect of IPC.
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Fig. 3 Impact of PI3K inhibition in IPC activated signalling cascades (Akt phosphorylations are depicted in panels A to D; GSK3b in panels E and F;
and PTEN in panels G and H). Bar graph shows the percentage of phosphorylation in all groups compared to the control group, expressed as
mean  S.E.M. (percentage of relative phosphorylation), n = 5 per group.
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IPC activates STAT3 through a PI3K-independent
mechanism
The SAFE pathway, which involves TNFa, JAK and STAT3, has been
described as an alternative RISK-independent cascade that may be
important for mediating the cardioprotective effect elicited by IPC in
some circumstances [13, 26]. We found that IPC significantly
increased levels of phosphorylated STAT-3 (Tyr705) during the trig-
ger phase (3.6  1.6-fold versus control, P = 0.009) (Fig. 4C). The
administration of wortmannin during the trigger phase did not alter
levels of phosphorylated STAT3. Similarly, IPC increases levels of
phosphorylated STAT3 in the mediator phase (2.6  0.5-fold versus
control, P = 0.049), and this was unchanged by the administration of
wortmannin during either the trigger or mediator phase (Fig. 4D).
Discussion
In our initial experiments, we confirmed previous observations that
PI3K activity is required during both the trigger phase and mediator
phase in order for IPC to reduce the infarct size. As expected, IPC
increased the levels of Akt phosphorylation during both the trigger
and mediator phases, as summarized in Figure 5. Interestingly, Akt
phosphorylation during both phases was completely abrogated by
PI3K inhibition during just the trigger phase or the mediator phase,
suggesting the existence of a memory effect. In contrast, one of the
kinases downstream of the PI3K/Akt pathway, GSK3b, was phospho-
rylated only during the trigger phase after IPC. PTEN was phosphory-
lated during both the trigger and mediator phases after IPC, but this
was independent of PI3K. IPC increases ERK phosphorylation during
both phases, but was only PI3K-dependent during the trigger phase.
Finally, STAT3, the kinase mediator of the SAFE pathway, was acti-
vated by IPC in both the trigger phase and mediator phase, and this
phosphorylation was independent of PI3K activity.
Role of PI3K in the protective effect of IPC at the
trigger phase and at reperfusion
IPC protects against myocardial IRI by activation of the RISK pathway
[10, 15]. Our data confirm the pivotal role of PI3K as mediator of IPC,
as its pharmacological inhibition either during the trigger phase or at
reperfusion abolished the IS-limiting effect provided by IPC. Wort-
mannin is a cell-permeable fungal metabolite that acts as a selective
and irreversible inhibitor of the PI3K catalytic activity that has been
widely used in pharmacological cardioprotection studies, but similar
results have also been demonstrated using the reversible inhibitor
LY294002 [15].









































































































































































































Fig. 4 Impact of PI3K inhibition in IPC
activated ERK (panels A and B) and
STAT3 (panels C and D). Bar graph shows
the percentage of phosphorylation in all
groups compared to the control group,
expressed as mean  S.E.M. (percentage
of relative phosphorylation, normalized by
its total), n = 5 per group.
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The fundamental concept of the RISK pathway may be summarized
in two ways: (i) short-term activation of these kinases is protective trig-
gering pro-survival pathways, whilst long-term activation may have
detrimental effects such as cell growth e.g hypertrophy; and (ii) their
activation occurs both during the preconditioning phase [27] and at
reperfusion [20]. It has been well established that these two phases
are crucial to mediate protection, as both of them can be pharmacolog-
ically intervened [28]. Taking into account that IPC signalling architec-
ture can be extrapolated to most cardioprotective therapies [29], we
focused on thoroughly dissecting the key signalling events occurring at
both phases when abolishing PI3K phosphorylation.
PI3K-Akt, one of the parallel cascades involving the RISK pathway,
has been described to activate a series of events. The activation of
PI3K by IPC promotes the phosphorylation of PDK1, which in turn
activates Akt to subsequently recruit a wide range of pro-survival
downstream targets such a GSK3b, p70s6k and eNOS [25]. On the
contrary, PTEN counter regulates the action of PI3K by dephosphory-
lating its product phosphatidylinositol(3,4,5)phosphate (abbreviated
as PIP3). The activation of the PI3K/Akt pathway inhibits mitochondrial
permeability transition pore (MPTP) opening, which is considered the
major downstream end-effector of the RISK pathway [10, 30].
Impact of PI3K inhibition in IPC activated
signalling cascades
Akt is a serine/threonine protein kinase. Its activity is primary con-
trolled by PI3K and PTEN through the modulation of PIP3 levels. Full
activation of Akt happens through the phosphorylation of a Thr-308
residue in the catalytic domain by PDK1 and a Ser-473 residue by
mTOR2, whilst its inactivation is mediated through dephosphorylation
of the two regulatory sites by the serine-threonine phosphatase
PP2A. Akt is widely used as surrogate marker for PI3K activation [31]
based on the assumption that its readout is proportional to PIP3
levels. However, both PIP3 levels and Akt activity can be the result of
both PI3K activation and PTEN inactivation and this fact needs to be
taken into account when interpreting our results. In our study, Akt
phosphorylation at both residues was abrogated in all preconditioned
hearts treated with wortmannin. Therefore, in preconditioned hearts
treated with the PI3K inhibitor, the abolishment of IS-sparing effect
was mirrored by lack of Akt phosphorylation.
GSK3b is a serine/threonine kinase that has been proposed to be
the downstream point of convergence of the RISK pathway, which
when phosphorylated (and thus inhibited) at serine-9 by Akt in
response to PIP3 increase [32], thus promoting inhibition of MPTP
opening [33], enhancing cell survival. [23]. Our data suggest that
GSK3b is phosphorylated at the trigger phase as a consequence of
PI3K activation, but this status is lost at the early reperfusion stage.
In agreement with our results, Tong et al. [32] have reported
increased phosphorylated levels of GSK3b following an IPC protocol,
which were blocked by wortmannin. Moreover, pre-treatment with
GSK3b inhibitors also mimicked the protective effect of IPC through a
reduction on myocardial IS [32]. In another study, pharmacologic and
genetic ablation of GSK3b failed to abrogate the protective effect con-
ferred by IPC [33]. Similarly, mice with a knockin of GSK3 beta
mutated at ser9 and ser21 remained amenable to protection by IPC
[23]. In that study, both insulin and cyclosporin A were effective in
delaying mitochondrial permeability transition pore opening in adult
cardiac myocytes from GSK3b knockin mice, therefore, suggesting
that mice lacking functional GSK3b can be protected through the
insulin-PI3K-Akt-mPTP axis, without the intervention of GSK3b. Over-
all, it appears that inhibition of GSK3b may play an important role
during the IPC protocol, but not afterwards. However, future studies
need to clarify the contentious role of GSK3b in cardioprotection.
The activation of pro-survival protein kinases has been studied in
great detail in the context of preconditioning. However, little is known
about the role of the phosphatases in this setting. Inhibition of phos-
phatases (PP1 and PP2A) during the preconditioning phase have
been shown to abolish the protective effect of preconditioning, whilst
its activation during reperfusion improved protection in precondi-
tioned hearts [34]. The ability to up-regulate the RISK pathway by the
use of phosphatase inhibitors during the early reperfusion phase is
considered an attractive and unexplored approach to limiting IRI.
PTEN is a dual lipid and protein phosphatase that antagonizes
PI3K/AKT signalling pathway. Whereas PI3K activity results in an
increased production of the second messenger PIP3 to activate the




















Fig. 5 Summary of our findings.
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pro-survival downstream cascade, PTEN dephosphorylates PIP3 to
PIP2 to down-regulate Akt activation. The phosphorylation form of
PTEN is considered inactive. After dephosphorylation, PTEN is acti-
vated but is also degraded rapidly as its half-life is substantially
reduced [35]. Therefore, the phosphorylation (inactivation) of PTEN
should be expected to induce cardioprotection following IRI, whilst its
dephosphorylated (activated) status should be expected to be detri-
mental [36, 37]. Interestingly, our results suggest that IPC induces
inhibition of negative regulator PTEN. This observation is in line with
the study of Cai and Semenza who identified a reduction in the activity
of PTEN following IRI in an isolated perfused rat heart model [35].
Furthermore, PTEN haploinsufficiency mice have been shown to
reduce the threshold of protection in IPC [38]. This result suggests
that IPC not only activates pro-survival kinases but also inhibits their
major counter regulators (i.e. PTEN, PP1 and PP2A). Additionally,
IPC-mediated PTEN phosphorylation appears to be independent of
PI3K, suggesting that both activation of PI3K and inactivation of PTEN
can work in unison, which may suggest that pharmacological inter-
vention of both proteins at the same time may produce synergistic
effect in the context of cardioprotection. Further studies need to be
undertaken to explore this hypothesis. It is time for PTEN to gain fur-
ther attention and respect in cardioprotection, as it still remains an
unknown player despite its crucial role in regulating Akt.
Impact of PI3K inhibition in IPC activated ERK
and STAT3
Cardioprotective signalling has been described as highly interactive
[29]. Within the RISK pathway, some studies have suggested cross-
talk between the PI3K-Akt and the ERK1/2 cascades, demonstrating
that inhibiting one cascade activates the other one and vice versa
[12]. Our study shows that ERK is phosphorylated following an IPC
stimulus, but partially inhibited after the administration of the PI3K
inhibitor wortmannin. These results may suggest a PI3K predomi-
nance during the IPC early trigger phase, although they contrast with
the lack of effect of the PI3K inhibitor on ERK phosphorylated levels at
reperfusion. In this context, a previous study from our laboratory
using a pharmacological approach with specific PI3K and ERK inhibi-
tors in the isolated perfused rat heart model suggested that the cross-
talk between PI3K/Akt and ERK is not balanced, with the PI3K cascade
playing a more determinant role in mediating cellular survival [12].
The SAFE pathway, which involves TNFa, JAK and STAT3, has
been described as an alternative RISK-independent cascade mediat-
ing the cardioprotective effect elicited by IPC. The cardioprotective
effect of STAT3 is believed to be partly related to its translocation to
the mitochondria by modulating respiration and inhibiting the mPTP
opening [39]. Like its RISK counterpart, the SAFE pathway is also
activated during both the IPC stimulus and the early phase of reperfu-
sion to protect the heart against IRI [9, 13]. We found that STAT3 is
activated following an IPC protocol, and this is unaffected by the inhi-
bition of PI3K. Interestingly, upon administration of wortmannin, the
protective effect elicited by IPC was lost despite the STAT3 pathway
being activated. Our results differ from those described by Lecour
et al. [13] in adult mouse cardiomyocytes, in which wortmannin
administered during the IPC trigger phase decreased STAT-3 phos-
phorylation and abolishing the protection afforded by IPC. However,
in our study, the mean infarct size for hearts treated with PI3K inhibi-
tor is approximately in a half-way point between the preconditioned
and the non-preconditioned hearts. This difference has been enough
to abolish statistical significance but leaves further room to speculate
on the involvement of more than one signalling cascade to promote
maximal protection, as it has been demonstrated that using a STAT-3
inhibitor also abolishes the protective effect of IPC [13]. Rather than
contradict, our results seem to complement the concept of having
multiple protective pathways, namely both RISK and RISK-indepen-
dent pathways. This may be important in establishing a cardioprotec-
tive stratagem that is effective in patients [2].
In the light of our data, we hypothesize that PI3K has a dominant
role to mediate the IPC protective effect. On close examination, the
activation of the p85 regulatory subunit of PI3K has been demon-
strated to control the serine phosphorylation of STAT3, a critical step
for the formation of stable STAT3 homodimers [40]. In other con-
texts, STAT3 activation has also been shown to be dependent on PI3K
recruitment [41], thus suggesting that PI3K can regulate STAT3 phos-
phorylation. Despite this evidence supporting a predominant role for
PI3K in IPC, other alternative pathways have been demonstrated to be
involved in a RISK-independent manner. Hence, cardiac-specific
STAT3 deficient mice have been unable to show Akt phosphorylation
following an IPC stimulus, and the pharmacologic preconditioning
induced by TNFa have demonstrated protection through STAT3 phos-
phorylation without involving PI3K activation [9]. To our understand-
ing, the activation of both the RISK and the SAFE pathway can occur
concomitantly either in IPC or in pharmacologic conditioning [14]. It
is also unknown whether activation of the two pathways provides an
additive effect to maximize the protection.
Limitations of the study
Only one PI3K inhibitor was used, and its effect when administered
alone was not tested, although many previous studies have shown
that wortmannin does not have major effects on IS and protein phos-
phorylation in the absence of IPC [15, 18]. Wortmannin may inhibit
other kinases such as myosin light chain kinase or PI 4-kinase at con-
centrations higher than that required for inhibition of PI3K. With
regard to protein analyses, not all phosphorylated residues were stud-
ied here—that is PTEN possesses three phosphorylation sites
(Ser380, Thr382 and Thr383) and STAT3 can be phosphorylated at
both its serine 727 and tyrosine 705 residues. Of note, we lack results
involving other important mediators in the IPC-induced molecular sig-
nalling, such as PKC—many other kinases and proteases remain to
be explored in this setting.
Our results are based on the assumption that Akt phosphorylation
is the result of the activation of PI3K by IPC, but we have no direct
evidence that IPC increases PI3K activity in the heart. However, we
have also shown an IPC-mediated PTEN phosphorylation that appears
to be independent of PI3K and could also result in the increase in Akt
phosphorylation levels. In this study, we cannot distinguish between
the amount of Akt phosphorylated by PI3K activation or PTEN
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inactivation, although we have shown that wortmannin abolishes both
the protective effect of IPC and the phosphorylation of Akt. Therefore,
caution is needed when interpreting the source of Akt activation
affords by IPC, as PIP3 levels are regulated by both PI3K and PTEN.
Further studies need to be undertaken to explore the actual contribu-
tion of the kinase PI3K and the phosphatase PTEN to the rise of PIP3
and subsequent Akt activation.
An additional limitation of the study is that we did not use func-
tional assessment of the heart to try and avoid potential manipulation
injury, as it has been shown that an intraventricular balloon can influ-
ence the salvage pathways being investigated [42].
Summary and conclusions
In summary, PI3K activity is required during both the trigger and
mediator phases for IPC to limit the infarct size. IPC increased the
levels of Akt phosphorylation during both the trigger and mediator
phases and this effect was fully abrogated by PI3K inhibition in
both phases, whilst its downstream GSK3b was phosphorylated
only during the trigger phase after IPC. Both PTEN and STAT3 were
phosphorylated during both the trigger and mediator phases after
IPC, but this was independent of PI3K. IPC increase ERK phospho-
rylation during both phases, being only PI3K-dependent during the
trigger phase.
In conclusion, the RISK pathway is recruited not only by IPC, but
also by other agents and its activation at early reperfusion is
considered a unifying pattern of cardioprotective signalling [8]. Fur-
ther elucidation of the signalling pathways behind the IPC-induced
protective effect is expected to reveal targets for cardioprotection,
which can be manipulated by pharmacological agents to benefit
patients undergoing acute myocardial infarction [2].
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